On Greek islands, refugees and migrants find themselves stuck – Washington Post

By Associated Press By Associated Press June 20 at 11:51 AM

In either direction, the waiting line is stuck.

On World Refugee Day, more than 60,000 refugees and migrants are stranded in Greece. Theyre eventually supposed to go forward to other countries in Europe or be sent back to Turkey, but the process is barely moving.

On the mainland, children take after-hours classes at Greek schools, while their families are moving out of tent camps and into trailers and apartments. Most will eventually be relocated to European Union (E.U.) countries, but the process is slow. Out of the total 63,000 places promised, just over 14,000 refugees have been moved out of Greece to 23 countries.

On the islands, where migrants are sent to wait for possible expulsion to Turkey, conditions for many have worsened as daily arrivals continue, though in smaller numbers than before. Another 14,000 people are waiting there.

Its all part of a refugee deal launched 15 months ago after more than a million people, most fleeing war and poverty in Syria, Iraq and Afghanistan, crossed into Europe in 2015 and 2016. Greece was a key transit point on that route, as refugees traveled from Turkey to nearby Greek islands, often using unsafe boats.

At first they were able to travel freely on to wealthier countries in northern and western Europe, but tens of thousands were stranded last year when the European Union began reintroducing border controls. Those who arrived before March 20, 2016, were allowed to move on to mainland Greece to seek relocation in an E.U. country. Those who arrived after are stuck on the islands. They can apply for asylum, or protection from being sent back but many are supposed to be sent back to Turkey. In practice, thats not really happening.

Shelters on Khos, a Greek island about five miles from the coast of Turkey, are filled beyond capacity. Many new arrivals, including infants, now sleep in tents on the beach.

Jill Biden, wife of former U.S. vice president Joe Biden, visited refugees in Khos earlier this month as part of work by the aid organization Save the Children. She traveled with Nitzia Logothetis, a therapist and aid organizer, who said she was horrified by the conditions she saw.

There were over 100 unaccompanied minors on the island, between the ages of 8 and 17, and over 1,300 refugees in total, Logothetis told a conference in Athens, the Greek capital, after returning from the visit.

I saw parents, children, and people who looked so hopeless, she said. Some of the children are so stressed out. ... The longer they stay, the more severe their symptoms.

Read the original:

On Greek islands, refugees and migrants find themselves stuck - Washington Post

In the Footsteps of Charles Darwin – New York Times

I had booked at the Floreana Lava Lodge beforehand ($138 per night), as it was the only lodging on the island for which I could find contact information. The lodge consists of luxury cabins complete with air conditioning (however the electricity is unreliable it is run on local pine nut oil). I was the only one staying there, mimicking my protagonist Frances isolation in a way I wasnt altogether comfortable with, but the next morning Claudio Cruz, who manages the property, sat down with me to a wonderful breakfast of fresh fruit grown on the island and local yogurt and cheese, to talk about his life.

Mr. Cruz is a native of Floreana, the son of 1940s settlers. He and his wife also own a guesthouse, the Casa Santa Maria. Besides Mr. Cruzs properties there are five other lodging establishments; the most famous is the Hotel Wittmer, right on Black Beach (named for its black volcanic sand), which heats up to infernal temperatures and is overrun twice a day with groups of tourists who come and snorkel and then go back to their boats. Each room at the Wittmer has a balcony with a hammock. The other guesthouses are clean and comfortable, with bathrooms en suite. Some have air conditioning and include breakfast, at $30 to $40 a night. There is usually a vacancy, unless there is a school group or a large scientific research community. Each guesthouse consists of two or three rooms atop the proprietors house.

Floreana, with a small population of about 200, is not for the easily lonely. There are no stores and no real restaurants, and you are not allowed to bring any produce to the island (though granola bars, instant oatmeal and other packaged foods are fine), for fear of contamination. Erika Wittmer and her mother Floreanita will make dinner for $10 and, if you sweet talk them into it, lunch ($6). Oddly, if only because the Fruleins Wittmer have never lived there, it is German food: pork, spaetzle, overcooked vegetables, a bit heavy for a tropical island. Claudio Cruzs sister, Aura, cooks tastier food out of her home and restaurant youll see the sign marking La Canchalagua. She will serve you at one of the two tables on her front porch if arrangements are made with her in advance. Meals are local fish and simple grilled meats, rice and vegetables (lunch $6, dinner $10 to $12). Nowhere on Floreana do you get to choose your meal (though accommodations may be possible for vegetarians and others with dietary restrictions).

The main attraction is Asilo de la Paz (Haven of Peace), site of the first human settlements on Floreana, in a cave near the only source of fresh water on the island. Its about five miles up the only road. You can take the workers bus, which leaves at 7 a.m., and ask to be dropped off ($2). Technically its national parkland, so youre not allowed there without a guide, but I went several times and was questioned only once. The cave is empty now, and just big enough for five people to stand its hard to believe an entire family once lived there. Also at the summit is an abandoned resort that the Wittmers built but never actually used, as well as the Floreana tortoise breeding corral, where you can commune with (and get close enough to touch) giant tortoises, cousins of the originals.

Better still: Attach yourself to a group. One day I caught a ride with a class of Ecuadorean fifth graders and listened as their guide explained the site while we shared lollipops. Another day I was invited to join a German group, and we stopped at a farm to examine the plants that provide the food to islanders. A third day, I asked Mr. Cruz to show me his farm, and the site of some of the human settlements that provide Floreanas historical lore (I paid him $20 for his time).

Floreana has some of the most interesting human history in the Galpagos, and was the site of the possible murder of three flamboyant characters, entertainingly chronicled in the 2013 documentary The Galpagos Affair: Satan Came to Eden. (I fictionalized them in my novel.) Originally occupied mostly by marauding pirates and buccaneers (who are said to have eaten all the tortoises, and released goats and rats), consistent human settlement on Floreana only dates back to 1929, when a German doctor, Friedrich Ritter, and his companion, Dore Strauch, decided to follow his nativist philosophy by leaving their respective spouses (who conveniently moved in together), pulling out all their teeth to seal their commitment to vegetarianism, and moving there. Their solitude was disturbed by the arrival of the Wittmer family in 1932. Relations between the two German families were tense, and the discord was further fueled when Eloise Wehrborn de Wagner-Bosquet, an Austrian baroness, arrived to stake her claim to the island. Competing narratives can be compared in Margaret Wittmers memoir, Floreana, and Strauchs memoir, Satan Came to Eden.

Arriving with two German lovers, the self-proclaimed baroness antagonized both families by stealing provisions and otherwise attracting attention. After a split in the mnage trois, the baroness and one of her partners vanished. Everyone on the island would seem to have had motive and opportunity for their disappearance, but accidents can also happen on volcanic islands. In the wake of her disappearance the spurned lover caught the next boat. His desiccated body was found on a deserted island nearby, six months later. Not long afterward, Dr. Ritter died from eating spoiled potted meat (despite his professed vegetarianism). Amid rumors that she had poisoned him, Dore Strauch returned to Germany, leaving the Wittmers briefly alone on the island. The Floreanita mentioned earlier is Margarets daughter.

If the murder stories dont scare you off, the snorkeling is terrific around Floreana. Its best to bring your own equipment, though there is usually some knocking about that you can borrow at hotels. There were five foreigners staying on the island the week I was there, and two Argentine girls negotiated a snorkeling trip with a local resident. The American couple who joined us were avid snorkelers, and they pointed out manta and eagle rays, small sharks and different kinds of colorful fish as well as spectacular underwater volcanic rocks.

In addition to the road that goes to the top of the island, there is a second one that runs parallel to the shore and ends in La Loberia, a sea lion nursery. I had been warned that the 800-pound bull that lives there is territorial, and when he barked at me angrily I knew Id gotten too close.

Go here to read the rest:

In the Footsteps of Charles Darwin - New York Times

DEC would change islands camping – The Adirondack Daily Enterprise

The state Department of Environmental Conservation is proposing numerous changes to the Saranac Lake Islands Campground, located just outside of Saranac Lake. In one form or another, the state has regulated camping on Middle and Lower Saranac lakes, as well as on Weller Pond and First and Second ponds, for just over a century. (Enterprise photo Justin A. Levine)

SARANAC LAKE Little more than a century after camping first opened on Lower and Middle Saranac lakes, the state Department of Environmental Conservation is proposing changes to both the regulations governing the campground and the locations of some of its sites.

Officially sanctioned state camping began on the lakes in 1916 and eventually expanded to include 300 wooden tent platforms scattered around the lakes, islands and connected ponds. The popularity of the platforms led to unsustainable use, and the state removed the platforms and created the Saranac Lake Administrative Camping Area, which opened in 1977.

The camping area, now known as the Saranac Lake Islands Campground, initially opened with 62 sites, all located on Lower Saranac Lake. In 1992, the DEC reorganized the campground, adding another 25 sites on Middle Saranac Lake and Weller Pond to bring the campground to its current total of 87 sites.

However, the DEC failed to change its rules and regulations to reflect the expansion of the campground, and is now proposing to do so through the recently released Saranac Lakes Wild Forest Unit Management Plan.

The Saranac Lake Islands Campground is operated by the DEC, one of more than a dozen such campgrounds throughout the Adirondacks. From the middle of May to the middle of October each year, sites in the campground are available to rent, and can be reserved up to nine months in advance.

However, while the state-owned shoreline of Lower Saranac Lake is administered under the campground rules, Middle Saranac Lake and Weller Pond shorelines are considered wild forest. This means that while there is no camping on Lower Saranac Lake except at the campground sites, there could be camping along the shoreline of Weller Pond and Middle Saranac Lake in places that are not official campground sites.

The DEC is proposing to expand the campground regulations to the shoreline of Weller Pond and Middle Saranac Lake so that no camping within 1,000 feet of shore would be allowed, except at the existing campground sites.

In addition to the regulations change, the DEC is also proposing to relocate 14 of the campground sites over three years to meet separation guidelines. Many DEC campgrounds are classified as intensive use areas, which means that campsites can be close together. But due to the administrative classification of the islands campground, sites need to be about 500 feet apart. Therefore, DEC plans to close some current sites and move them to other locations where the separation requirements will be met. Twelve of these sites are on Lower Saranac Lake, while the other two are on Middle Saranac Lake.

The DEC is also proposing to build four new sites and says it will work with the state Adirondack Park Agency to develop several new group camping sites, which allow more than six people. DEC campgrounds limit most sites to a maximum of six.

The DEC has put presentations and fact sheets about various aspects of the Saranac Lakes Wild Forest UMP on its website and will take public comments on the proposals until Aug. 11. For the fact sheets, presentations and the full UMP, along with public meeting dates and information on how to submit comments, go to http://www.dec.ny.gov/lands/22593.html.

SUGAR BUSH A mother and her young daughter were involved in a one-car crash on state Route 3 on ...

BLOOMINGALE A New Hampshire man was taken to the hospital Saturday after he crashed while riding on River Road ...

SARANAC LAKE A judge has blocked Lake Side Motel owner David Manning from selling his property while a lawsuit ...

See the original post:

DEC would change islands camping - The Adirondack Daily Enterprise

Paradise saved: some of world’s rarest birds rebound on Pacific islands cleared of invasive predators – BirdLife International

Just two years after ambitious efforts by a team of international conservation organisations to rid French Polynesias Acteon & Gambier island groups of invasive mammals began, five of six targeted islands are now confirmed as predator-freea ground-breaking one thousand hectares in total. Early signs already indicate that rare birds found nowhere else in the world (endemic) and other native plants and animals are recovering as the remote islands return to their former glory.

The Polynesian Ground-dove Alopecoenas erythropterus (locally known as Tutururu) is one of the rarest birds on the planet with fewer than 200 individuals left. Predation and competition by destructive, non-native (invasive) mammals in French Polynesia have driven this and other rare, endemic bird species to the brink of extinction. The species is listed by BirdLife International as Critically Endangered on the IUCN Red Lista category that signals an extremely high risk of extinction within our lifetimes.

The Acteon Gambier island group is home to the last viable population of Polynesian Ground-dove, a species once much more widespread in the Pacific, said Steve Cranwell, BirdLife Internationals Invasive Species Manager. This birds remaining predator-free habitat was so small that without this intervention, a cyclone, prolonged drought, or accidental rat or avian disease introduction could trigger extinction.

Introduced mammalian species alone are believed to be responsible for 90% of all bird extinctions since 1500. Early human explorers introduced invasive species such as rats to the remote Acteon & Gambier islands (and thousands more around the world), upsetting the natural balances of the islands and threatening the native plants and wildlife that evolved without defences against land predators.

Operation Restoration

Combining resources, expertise, equipment, and logistical skills, a coalition of NGOs, BirdLife International, SOP Manu (BirdLife Partner, French Polynesia) and Island Conservationtogether with the support of the government of French Polynesia, landowners, other partners and local volunteersvoyaged over 1,500 km to six of French Polynesias remote islandsVahanga , Tenarunga, Temoe, Kamaka, Makaroa and Manui to complete the challenging project in 2015.

The project required years of planning and fundraising (including a cooperation with Rovio, the maker ofAngry Birds), involved nine permits, 165 helicopter flight hours, three ships transporting hundreds of tonnes of equipment and donated bait from key partners Bell Laboratories and Tomcat, as well as 31 personnel from six countries (from three continents) who endured extraordinary weather and sea conditions during 12-day journeys to and from the islands. The prospect of a brighter future for the Tutururu and other native island species made the operations well-worth the effort.

After extensive monitoring, a survey in April has confirmed great success on five of the six islands, reported Dr David Beaune, Director SOP Manu. This is a tremendous achievement that will provide a permanent solution to the alarming declines of native species on these islands due to predation and competition from invasive species.

Double benefits: safe habitat and local coconut production

The project has more than doubled the secure habitat for both the Polynesian Ground-dove and the Tuamotu Sandpiper Prosobonia parvirostris (locally: Titi), a globally Endangered landbird, said Cranwell. The islands look vibrant with new native vegetation, and both bird species have now established and are increasing on the island of Tenarungasomething that has not been possible for decades.

The benefits extend beyond nature alone. Without rats, local land managers reported a doubling of their copra (coconut kernel) production in 2016a major source of income for these isolated communities, said Pere Joel Aumeran Vicar General for the Catholic Church. Safeguarding our islands natural value is a foundation of Polynesian culture and important to the Catholic Church. This tremendous contribution to the lives of local people ensures these islands fully recover and remain predator-free; a legacy the Puamotu people leave for generations to come.

While the success of this project is vital to securing the future for these globally threatened birds, it also provides important safe habitat for other endemic species in a region where there is very little invasive-predator-free habitat, explained Richard Griffiths, Island Conservations Project Director. The success also serves as an indicator that invasive-species-driven extinctions on other remote islands can be avoided if this operation is replicated at scale.

Next steps

We now need to increase the habitat range of these species by translocating small populations to islands where they were previously founda conservation technique proven highly effective in Polynesia, said Dr. Beaune. Plans are underway to re-introduce the Tutururu and Titi to Temoe, and to attract other Endangered seabirds such as the Polynesian Storm-petrel Nesofregetta fuliginosa to these predator-free islands.

To inform future restoration efforts for complex islands with challenging terrain, the team is conducting an analysis of the Kamaka effort, which did not succeed. With invasive mammals now eradicated from the five islands, the coalitions attention is shifting to biosecuritypreventing re-invasion through monitoring, education (brochures and signs for tourists), and stringent inspections of incoming vessels.

French Polynesia can be immensely proud of completing this project, which, for its scale and complexity, is a first for the region, Griffiths said. The government of French Polynesia is well positioned to capitalize on this success and become a leader within the Pacific to rid Oceanias islands of damaging invasive species.

Polynesian Ground-dove album Tuamotu Sandpiper album Operation & landscapes album

2015 Press Release Coverage on BBC Earth Angry Birds video Island Conservation Blog coverage BirdLife Operation Restoration project updates

Species benefiting:

BirdLife International, withSOP Manu(BirdLife Partner in French Polynesia) andIsland Conservation lead an extensive island restoration operation in a remote area of French Polynesia to save Critically Endangered bird species and restore the delicate ecological balance. The ambitious project is restoring the Acteon & Gambier archipelagos to their former glory, making them once again safe and ready for the reintroduction of the Tuamotu Sandpiper and Polynesian Ground-dove, andbenefitingmany other wildlife.

By sharing transport, equipment and expertise, weve significantly reduced the cost of restoring several islands that are threatened, but the project is nonetheless our biggest of the decade. Additional technical assistance has come from the Pacific Invasives Initiative and the New Zealand Department of Conservation.

This project has received support from many international and national organisations with significant funding from the European Union, the British Birdwatching Fair, the David and Lucile Packard Foundation, The Mohamed bin Zayed Species Conservation Fund, and National Geographic Society; sponsorships from Bell Laboratories and T-Gear Trust Canada; and assistance from the Government of French Polynesia and many individual people around the world.

See original here:

Paradise saved: some of world's rarest birds rebound on Pacific islands cleared of invasive predators - BirdLife International

Are You a Magnet for Mosquitoes? – Scientific American

When it comes to attraction, the allure can begin even before she sets eyes on you. There seems to be something about the way youher dinnersmells from afar that makes you a desired target. While you are chatting with friends or overseeing the barbecue, that mosquito will go on the hunt and make you her next blood meal. But what makes you so attractive to tiny ankle biters?

This month a group of British researchers is launching a new investigation into the role of human genetics in this process. They are planning to collect smelly socks from 200 sets of identical and nonidentical twins, place the footwear in a wind tunnel with the bugs and see what happens next. The owners of the socks, the scientists hope, may naturally produce attractive or repellant chemicals that could become the basis for future mosquito control efforts. The researchers expect that studying the popularity of the garments the skeeters hone in onand analyzing both the odor compounds in them and the genetics of their ownerscould help.The study, which will include 100 twins each from the U.K. and from the Gambia, will start recruiting volunteers in the coming weeks.

We know very little about the genetics of what makes us attractive to mosquitoes, says James Logan, a medical entomologist at the London School of Hygiene and Tropical Medicine who is leading the work. Earlier studies suggest visual, olfactory and thermal (body heat) cues all help drive mosquito attraction. We hope this study will give us more insights into the mechanisms that help change our body odors to make us more or less attractive to mosquitos, he says. If we can identify important genes, perhaps we could develop a pill or medication that would allow the body to produce natural repellents to keep mosquitoes away. The findings, he adds, could also help epidemiologists improve their models for how vulnerable certain populations may be to disease-carrying mosquitoes.

Already scientists know there are differences among us that contribute to why some of us get bitten more. Those of us who exhale more carbon dioxide seem to be a natural beacon for mosquitoes, in particular. Researchers have also found a correlation with body size, with taller or larger people tending to attract more bitesperhaps because of their carbon dioxide output or body surface area. There is also some evidence women who are pregnant or at certain phases of the menstrual cycle are more attractive to mosquitoes. Other work has found that people infected with malaria are more attractive to malaria-carrying mosquitoes during their transmissible stage of infection.

But what of our individual genetics? Two years ago Logans team published a small study looking at 18 sets of identical twins and 19 sets of nonidentical twins and their attractiveness to mosquitoes. They found that identical twins were more similar in their desirability to the blood-sucking insects than the nonidentical twins. Because earlier work had found that identical twins smell more alike than nonidentical twins, the British researchers surmised genes may play a role in this mosquito attractiveness.

This new study aims to nail down some more concrete conclusions with its larger sample size and add another population into the mix. (Most research in this area has focused on European Caucasians whereas this study will also include twins from the Gambia). There are other differences that set this apart from their earlier work, too: The 2015 study had tested attractiveness among Aedes mosquitoesthose that carry dengue and Zikawhereas this study will test attractiveness among Anopheles mosquitoes, a species that can transmit malaria. The team suspects the different species will be attracted to the same volatile compounds in human odor but wants to explore this further.

This is novel work and its a good step. It will tell us if there are genetic differences or not but it wont be a complete answer about mosquito attraction because other factors like diet, wind, time of day and mosquito species can all influence that, says Zainulabeuddin Syed, a professor of biological sciences at the University of Notre Dame who studies the smell-influenced behavior and movement of insects and is not involved in the Logan project. Syeds work has found that people of various ethnic groups all seem to produce four major volatile compounds (although at varying levels) and there are some early hints that one compound in particular, called nonanal, may be particularly attractive, at least among certain species of mosquitoes.

Exactly what genes contribute to producing compounds that could possibly interest mosquitoes remains a vast unknown. Scientists that study human odors and genetics have previously suggested scent cues associated with genetics are likely controlled via the major histocompatibility complex (MHC) genes. Those genes appear to play a role in odor production and also in mammals mating choicesbecause humans and mice alike appear to prefer mates that smell less similar to themselves, which scientists have theorized may be a natural control against inbreeding. As a result, Logans team may target those odor-linked genes, but he says they are looking at all the options. In the next couple of years, he says, they hope to have some early answers. For now, and likely for many years to come, we can only slather on some bug repellant and hope for the best.

Visit link:

Are You a Magnet for Mosquitoes? - Scientific American

Here’s What We Know About The Senate GOP Health Care Bill – NPR

Senate Majority Leader Mitch McConnell, R-K.Y., seen speaking to reporters on Tuesday, is set to release a draft of the Senate's version of the Republican health care bill on Thursday. Chip Somodevilla/Getty Images hide caption

Senate Majority Leader Mitch McConnell, R-K.Y., seen speaking to reporters on Tuesday, is set to release a draft of the Senate's version of the Republican health care bill on Thursday.

Senate Majority Leader Mitch McConnell says Republicans will release a discussion draft of their version of the health care bill on Thursday, with a vote likely next week.

Private health care talks have been underway in the Senate for weeks. McConnell tapped a 13-member working group last month to hash out senators' differences over the House-passed American Health Care Act. McConnell's office has since taken the lead drafting the Senate version of the party's long-promised legislation to dismantle the Affordable Care Act.

Senate Republicans have been coy or simply out of the loop on the specifics in the Senate plan, but here is what we know about what might be in the bill and where it could be headed:

It Sounds A Lot Like The House Bill

After the House passed AHCA in early May, leading senators asserted that the Senate would go their own way. "We're writing a Senate bill and not passing the House bill," Sen. Lamar Alexander, R-Tenn., said then. "We'll take whatever good ideas we find there that meet our goals."

In the end, those goals appear to be aligned.

The structure of the Senate bill, as described by GOP senators and aides, appears fundamentally the same as the House-passed plan.

The Senate bill is also expected to repeal the individual mandate and all or most of the ACA's taxes, phase out the Medicaid expansion as well as change how the Medicaid program is funded, establish a system of tax credits to help people buy insurance if they choose, and make it easier for states to opt-out of the ACA's mandates for preexisting conditions and minimum insurance coverage mandates.

There will be changes. For instance, the Senate version is expected to include more generous tax credits to make sure older, poorer Americans don't get hit with higher costs. Republicans are also battling over how best to remake the Medicaid program, with key vote senators like Shelley Moore Capito of West Virginia sounding skittish about Medicaid reductions.

Other Republicans are excited by the bill. Sen. John Barrasso, R-Wyo., has been one of the most vocal advocates for Obamacare repeal. "People didn't want to have to buy this product. This is a sinking ship, people are ready to jump off," he said Tuesday. Republicans like Barrasso see the bill as a win for the GOP and for the promises they made on the campaign trail.

"We eliminate the individual mandate. You'll see more people as free citizens making a decision to not have Obamacare insurance, but certainly have more freedom," Barrasso said.

The Process Stinks

"Can you say it was done openly? With transparency and accountability? Without backroom deals and struck behind closed doors? Hidden from the people? Hell no you can't! Have you read the bill? Have you read the reconciliation bill? Have you read the manager's amendment? Hell no you haven't!"

That's not Senate Minority Leader Chuck Schumer in 2017, that was former Minority Leader John Boehner in 2010 before House Democrats passed the Affordable Care Act.

Republicans vilified Democrats seven years ago for negotiating the final details of Obamacare behind closed doors. Today Senate Republicans' response could be: We learned it from watching you.

The Senate has not held any public hearings on their health care bill (the House did), senators involved in the talks have been tight-lipped on the substance, and the public will only have a few days to see it before it gets a vote.

McConnell brushed off questions about transparency. "They'll have plenty of time," he told reporters Tuesday. "We've been discussing all the elements of this endlessly for seven years. Everybody pretty well understands it. Everybody will have adequate time to take a look at it."

That argument rings hollow with some of his fellow Republicans. "We used to complain like hell when the Democrats ran the Affordable Care Act. Now, we're doing the same thing," Sen. John McCain, R-Ariz., told CNN.

"If you're frustrated in the lack of transparency in this process, I share your frustration," Sen. Mike Lee, R-Utah, said in a Facebook video for his constituents. Lee is a part of the 13-member working group, but he said he hasn't seen the draft bill. "I just haven't been able to see it yet and as far as I know the overwhelming majority of my colleagues haven't been able to see it either."

Failure Is An Option

McConnell has been quietly leading Republicans' to a vote next week but that doesn't mean it's going to pass.

"We're going to make every effort to pass a bill that dramatically changes the current health care law," McConnell said when asked if he has the votes.

"I think the leader has made it pretty clear we're going to vote, one way or another, and hopefully we'll have 50 votes when that time comes," Senate Republican Conference Chairman John Thune said when asked if he believed McConnell would bring a bill to the floor that didn't have the votes to pass.

While no Republican senator has yet come out opposed the bill, McConnell has only a two-vote margin of error with many senators voicing problems with the legislation.

"If our bill comes in with greater subsidies than Obamacare, it makes it hard for conservatives to support a bill that actually has greater subsidies than Obamacare," Sen. Rand Paul, R-Ky., told reporters in regards to the tax credits in the GOP plan. "That for me is a nonstarter."

Conservatives like Ted Cruz of Texas and Mike Lee have Utah have been skeptical about the bill's ability to ultimately lower premium costs for Americans. Both are seen as potential 'no' votes on the bill.

More moderate senators like Susan Collins of Maine and Lisa Murkowski of Alaska are also seen as potential 'no' votes on the other end of the spectrum.

Defeat of the House-passed bill wouldn't necessarily end the health care debate in Congress, but it would redefine it.

Wisconsin GOP Sen. Ron Johnson hinted at what that would look like at a constituent event last Friday. "I'm not sure if we're going to come up with 50 votes with a Republican solution. Let's stabilize the markets and then, long-term, work with the Democrats colleagues to actually fix the healthcare system," Johnson said.

The White House Doesn't Love It Yet

The White House has maintained a light tough when it comes to shaping the policies in the health care bill, but President Trump reportedly told a group of senators last week that the bill passed in the House was "mean" and he wanted the final bill to do more to help needier Americans.

On Tuesday, White House Spokesman Sean Spicer told reporters the president "wants a bill that has heart in it" but did not offer any specific policies Trump wants in the bill. Spicer also said he didn't know if the president had seen a draft of the Senate bill.

If the Senate approves a bill next week, it still has more hurdles to go. The House either needs to pass the Senate bill as-is and send it to Trump's desk, or the House and Senate have to go into a third round of negotiations in which both chambers would have to vote again on a final, compromise bill.

Either way, the health care debate is likely to continue into July if the Senate can pass a bill next week.

Democrats Debate How Far To Take Their Fight

Senate Democrats can't filibuster the bill because it's protected under special budget rules and only requires a majority vote. They're all going to oppose it, but they can't ultimately stop it from eventually getting an up-or-down vote.

Democrats have started a series of protests this week that could intensify as the Senate approaches that vote. They held the floor Monday evening for a series of speeches in opposition to the bill. On Tuesday, they invoked a rule to block any committee hearings from taking place that afternoon to draw attention to their opposition to the health care bill.

Outside Democratic activists associated with Indivisible are calling for Democrats to use every procedural tactic available to slow down debate. Since amendments are unlimited on a bill like this, one activist has even called on Democrats to introduce 40,000 amendments to keep the Senate on the bill through the 2018 midterms.

It's unclear how Democrats will respond next week, but Schumer said Republicans should expect a fight. "If Republicans won't relent and debate their health care bill in the open for the American people to see, then they shouldn't expect business as usual in the Senate," Schumer said in a statement.

NPR congressional reporters Scott Detrow and Geoff Bennett contributed to this report.

The rest is here:

Here's What We Know About The Senate GOP Health Care Bill - NPR

Spicer: Trump wants a health care bill ‘that has heart’ – Politico

By Nolan D. McCaskill

06/20/2017 02:16 PM EDT

Updated 06/20/2017 02:28 PM EDT

President Donald Trump clearly wants a health care bill with heart, White House press secretary Sean Spicer said Tuesday.

Days after telling Republican senators that the Houses American Health Care Act was mean, the president reportedly told tech leaders on Monday that the Senates version needs more heart, an ambiguous comment Spicer was asked to clarify on Tuesday.

Story Continued Below

I mean, the president clearly wants a bill that has heart in it, Spicer said. He believes that health care is something that is near and dear to so many families and individuals. He made it clear from the beginning that that was one of his priorities, and as the Senate works its way through this bill, as the House did, any ideas are welcome to strengthen it, to make it more affordable, more accessible and deliver the care that it needs.

Spicer described health care as an issue Trump is passionate about. He understands the role that health care plays in so many peoples lives and their families, and he wants to make sure that we do everything we can to provide the best option for them as Obamacare continues to fail, he said.

Asked specifically what part of the Senates bill Trump takes issue with, Spicer pointed to the ongoing discussion Trump has had with senators.

Im not gonna get into the private discussions that have occurred, he said. But I will just say that the more that we can do to produce a bill as it works its way through the process, that achieves the presidents goals, I think thats something that we can all agree on.

The text of the Senate bill could be made public for the first time on Thursday, giving senators roughly a week to review the text before a floor vote. Democrats have hammered their GOP colleagues for what theyve said is a secretive process that keeps Americans and even some Republican lawmakers in the dark.

Sign up for POLITICO Playbook and get the latest news, every morning in your inbox.

By signing up you agree to receive email newsletters or alerts from POLITICO. You can unsubscribe at any time.

Spicer couldnt say Tuesday whether Trump has seen the legislation. I dont know that, he told reporters. I know that there was some chatter today. I know the president has been on the phone extensively with the leader and with key senators. So I dont know if hes seen the legislation or not, but I know that theyve been working extremely hard and the president has been giving his input and his ideas, feedback to them, and hes very excited about where this thing is headed.

Spicer also couldnt confirm whether any White House staffers have seen the bill. I dont even know where we are in terms of a final plan, he conceded. But I know that they are up there working hand in glove with them.

Missing out on the latest scoops? Sign up for POLITICO Playbook and get the latest news, every morning in your inbox.

Continued here:

Spicer: Trump wants a health care bill 'that has heart' - Politico

Goodnight, Health Care – Washington Post (blog)

While Obamacare was under consideration, McConnell had strong words for the Democratic majority's tactics, criticizing them for going 'the partisan route.' Now, he seems to be using them. (Meg Kelly/The Washington Post)

In a dark, dark wood-paneled room Down a dark, dark hall Down a dark, dark staircase In a dark, dark building Down another equally long hall Past a row of statues And three ominous guards And two American flags And a man whispering hush And a series of paintings of the Founding Fathers in various attitudes of saintliness and undress Through several thick doors Inaccessible to journalists and far from the keen eyes of the Senate Behind a pile of papers And another pile of papers In a dark, dark box There is The Senate version of the health-care bill. Which of course everyone knows about and which has been discussed perfectly openly.

Do not fear the Senate version of the health-care bill, my child. It is perfectly secure, behind those locked doors and the press secretaries holding silent fingers to their lips. We discussed this concept several years ago, and so no further discussion is needed. Besides, if someone saw it who was not already pure in heart (which includes many in the GOP caucus but excepts McConnell staffers) it might fill them with an unspeakable dread and cause chaos to rein throughout the land, and town halls might be full of yelling and discord instead of joy and mirth.

Therefore, it must be kept there under lock and key, lest it escape and bring disharmony among the people. They would not be able to breakfast in comfort because fear would grip them as they gazed down into their cereal bowls. It might alarm them. They would come and make loud complaints. They would not wish immediately for their senators to vote for it, and it might be allowed to devour entire weeks of the discourse. That is why Sen. Mitch McConnell has undertaken to guard it by day and by night, so that the people may not be startled, and that it will be seen only for a short time, so that our eyes may bear it. He is only protecting us from the things this bill will do. Those few who have laid eyes on it have been stricken silent with amazement, and their faces have appeared on the television across the land crying in anguish (although not so often as you might expect). It is good that this thing has been contained and is being kept safe behind closed doors where it can be revised safely. For if it were allowed to escape early it would be quite startling indeed and who knows what changes might have to occur.

So it remains in that dark room Down those dark stairs Surrounded by men in dark suits (and sometimes seersucker) For who knows what may happen if it is seen? It may even turn people to stone. It may harm you once it gets out, if it sees you. But in the meantime it is safely locked away Down a dark, dark staircase In a dark, dark wood-paneled room In a deep, deep swamp And no debate is needed.

Read more from the original source:

Goodnight, Health Care - Washington Post (blog)

John Kasich and John Hickenlooper: Another one-party health-care plan will be doomed to failure – Washington Post

By John R. Kasich and John W. Hickenlooper By John R. Kasich and John W. Hickenlooper June 20 at 2:26 PM

John R. Kasich, a Republican, is governor of Ohio. John W. Hickenlooper, a Democrat, is governor of Colorado.

(Meg Kelly/The Washington Post)

The fate of Americas health-care system, the focus of our nations most important and most heavily politicized public-policy debate is in the hands of the Senate, where senators get their turn to find a balanced and sustainable approach to health-care reform.

It is clear that the bill passed by the House in May will not meet the challenges of our health-care system. This bill calls into question coverage for the vulnerable, fails to provide the necessary resources to ensure that no one is left out and puts the health and well-being of millions of hard-working people in our states at risk, while shifting significant costs to the states. Medicaid provisions included in this bill are particularly problematic.

All Americans will come out on the losing end if we simply replace one divisive plan with another, having failed to find a bipartisan solution to bringing lasting reform that can be sustained across administrations. It will be worse yet if senators like House members before them decide these questions behind closed doors, avoiding the open discussion and transparency needed to make the American people full participants in this vital debate.

We certainly agree that reforms need to be made to our nations health-care system. But as governors from opposite sides of the political aisle, we feel that true and lasting reforms are best approached by finding common ground in a bipartisan fashion.

Along with other governors Democrats and Republicans we agree that the best place to start is to restore stability to our nations health insurance system.

We and other like-minded governors have been working together to create a blueprint that can result in an improved health insurance system that is available and affordable for every American. We recognize that this is not an easy task. That is why our first step has been to develop a set of guiding principles that will positively impact the coverage and care of millions of Americans, including many dealing with mental illnesses, chronic health problems and drug addiction. These principles:

Improve affordability: Insurance reforms that increase access to quality, affordable health insurance coverage must be coupled with reforms that address rising health-care costs. Insurance reforms should be made in a manner that is consistent with sound and sustainable cost-control practices.

Restore stability to insurance markets: Americans without access to employer-sponsored coverage or government plans need to be able to choose from a healthy, stable and competitive market of insurers.

Provide state flexibility and encourage innovation: As laboratories of democracy, states can develop innovative approaches with the potential to strengthen health insurance for all Americans. Within broad standards, states should have appropriate flexibility to implement reforms in a manner that is responsive to local and regional market conditions.

Improve the regulatory environment: As the principal regulators of insurance, states are in the best position to promote competition within state insurance markets. Federal efforts should limit duplicative and burdensome regulations and provide relief to small-business owners and individuals.

The Affordable Care Act expanded coverage, but it needs improvement. Uncertainty in our current health insurance market has helped make it unstable. As passed by the House, the American Health Care Act threatens to create greater uncertainty. Historically, one-party solutions are not sustainable. The bipartisan principles we propose provide a more stable starting point to bring Republicans and Democrats together on lasting reforms.

Ensuring that quality health insurance is available and affordable for every American is a bipartisan responsibility. The states are uniquely positioned to meet this responsibility and to make our health insurance sector vibrant, stable and fair.

As governors, we and our colleagues who have signed on to this effort stand ready to work with our congressional delegations to develop a proposal that is fiscally sound and provides affordable coverage for our most vulnerable citizens. Our states and all Americans deserve nothing less.

See the rest here:

John Kasich and John Hickenlooper: Another one-party health-care plan will be doomed to failure - Washington Post

Trump wants health care bill with ‘heart’ – Washington Times

The White House said Tuesday that President Trump wants to make sure the health care bill being drafted in Congress has heart and improves the health care system for all Americans.

The president clearly wants a bill that has heart, White House press secretary Sean Spicer said at the daily press briefing.

Mr. Trump reportedly said at a closed-door meeting Monday with tech industry leaders that he wanted the Senate to come up with a bill that had more heart than the bill the House passed in May, which was criticized for cutbacks in the Medicaid program for the poor.

Mr. Spicer did not say where the president believed the House bill lacked heart.

Senate Republicans are working on a separate health care bill. The details remain under wraps.

The president welcomes any ideas to strengthen it, to make it more affordable, more accessible and deliver the care it needs, Mr. Spicer said.

[Mr. Trump] believes that health care is something that is near and dear to so many families and individuals, he said. He made it clear from the beginning that that was one of his priorities. He wants to make sure we do everything we can to provide the best option for them as Obamacare continues to fail.

Read the original:

Trump wants health care bill with 'heart' - Washington Times

Few feel they have good understanding of GOP health care plan – CBS News

By Jennifer De Pinto, Fred Backus, Kabir Khanna and Anthony Salvanto

As Republican leaders push forward to repeal and replace Obamacare, most Americans would prefer a public discussion take place in the Senate, feeling they don't have a good understanding of what the plans would do. From what they do know, or anticipate, by two to one, more believe the plans will hurt them rather than help them. And the bill passed recently by the House gets majority disapproval.

Almost three quarters -- including most Republicans --feel that Senate Republicans should discuss their health care plans publicly as they work on the bill. Republicans are, however, twice as likely as both Democrats and independents to endorse a private approach.

Perhaps this is because most Republicans, Democrats, and independents agree they haven't heard enough to feel they have a good understanding of the Republicans' plans yet.

Still looking for information, many start off as skeptical. Most Democrats and nearly a third of independents think the GOP health care plans will hurt them personally. More than half of Republicans anticipate no effect on them personally.

Women and lower-income Americans are particularly likely to say they will be hurt personally by the plans.

Few feel positively toward the bill recently passed by the House of Representatives. Overall, 32 percent approve of the bill, while 59 percent disapprove. Views are divided by partisanship.

Meanwhile, most Americans would prefer that Congress improve the Affordable Care Act, not repeal it, including half of Republicans who don't want it repealed entirely. Overall, seven in ten say the law should either be kept in place or that it has some good things but needs changes to make it work better. Fewer than three in ten say Congress should repeal and replace it entirely.

This poll was conducted by telephone June 15-18, 2017 among a random sample of 1,117 adults nationwide. Data collection was conducted on behalf of CBS News by SSRS of Media, PA. Phone numbers were dialed from samples of both standard land-line and cell phones.

The poll employed a random digit dial methodology. For the landline sample, a respondent was randomly selected from all adults in the household. For the cell sample, interviews were conducted with the person who answered the phone.

Interviews were conducted in English and Spanish using live interviewers. The data have been weighted to reflect U.S. Census figures on demographic variables.

The error due to sampling for results based on the entire sample could be plus or minus four percentage points. The error for subgroups may be higher and is available by request. The margin of error includes the effects of standard weighting procedures which enlarge sampling error slightly.

This poll release conforms to the Standards of Disclosure of the National Council on Public Polls.

2017 CBS Interactive Inc. All Rights Reserved.

See the article here:

Few feel they have good understanding of GOP health care plan - CBS News

Defunding Planned Parenthood needs to take priority in the Senate healthcare bill – Washington Examiner

As the healthcare bill makes its way through whatever the Senate is doing with it, one provision is absolutely non-negotiable: The bill needs to defund the nation's largest abortion giant, Planned Parenthood. They committed 328,548 abortions last year, which is equal to one of every three abortions in the country.

Just because the Hyde Amendment states that taxpayer monies cannot be used to directly fund abortion, it does not prohibit tax dollars from paying for the costs to keep the abortion facilities up and running, the salaries of staff, or the medical equipment used for abortions.

What other government contractor takes hundreds of thousands of innocent lives per year and still receives taxpayer dollars?

The list of reasons why Planned Parenthood needs to be immediately defunded is long and egregious.

We know that Planned Parenthood illegally profited from selling the body parts of babies they aborted. Planned Parenthood and their affiliates have even been referred for criminal prosecution by the House of Representatives' Select Panel on Infant Lives as well as the Senate Judiciary Committee.

The abortion giant has defrauded taxpayers out of millions of dollars: In 2009, the Alliance Defending Freedom released an audit that showed affiliates in at least four states were responsible for more than $95 million in waste, abuse, and potential fraud over the course of several years. Planned Parenthood of California was accused of overcharging the state and federal governments by $180 million for birth-control pills. And in 2013, Planned Parenthood was ordered to pay more than a million dollars in restitution because they defrauded taxpayers in Texas.

Planned Parenthood has suffered no reduction in government funding even after they were caught numerous times aiding and abetting sex trafficking of minor girls and covering up statutory rape at many of its affiliates.

Planned Parenthood in Cincinnati, Ohio, was sued after covering up sexual abuse of a minor by her father. In another case in the same state, they failed to report the sexual abuse of a 13-year-old by her soccer coach.

Planned Parenthood Rocky Mountains was sued after committing an abortion on a teen girl without parental consent, failing to report child sex abuse, and then returning her to her abuser her step-father.

In California, swim coach Andrew King was allowed to sexually abuse dozens of young girls after Planned Parenthood failed to report child sex abuse when he took a 14-year-old he impregnated there for an abortion.

As if covering up child abuse wasn't horrible enough, women have died because of Planned Parenthood's carelessness, the most recent being Cree Erwin-Sheppard in 2016, who perished after a botched abortion in Michigan.

The abortion giant could care less about the well-being of their patients.

A Kentucky Planned Parenthood broke the law when they started doing unlicensed abortions at their new facility. The Columbia, S.C. Planned Parenthood was cited for 21 health and safety violations and ordered to pay $7,500. They broke HIPAA privacy laws in California when they gave patient information to a vendor, and Planned Parenthood in Delaware was shut down after numerous health violations, including not cleaning their instruments.

Planned Parenthood also knew about the atrocities that Kermit Gosnell was committing at his late-term abortion facility and chose to do nothing.

And here's the kicker to this entire list of atrocities: Planned Parenthood gets more government money every year but serves fewer people. By their own annual reports, between 2006 and 2016, the number of clients served by Planned Parenthood dropped 22.5 percent. Their revenue rose by 33 percent since 2007. Under Cecile Richards' leadership, cancer screenings and prevention services have dropped by 66 percent.

Yet they continue to receive government funding because they spend millions of dollars in Washington and are a force to be reckoned with. Just this past election cycle, Planned Parenthood had a ground operation larger than Hillary Clinton's paid staff and pledged to spend $30 million to elect her. They also gave 99 percent of their donations to Democrats.

But their time is up. Anti-abortion elected officials need to deliver on their promises during the campaign to defund Planned Parenthood. The nonprofit is a corrupt, deceitful, and harmful organization that should not be funded by taxpayers in any way at all.

Kristan Hawkins (@KristanHawkins) is a contributor to the Washington Examiner's Beltway Confidential blog. She is president of Students for Life of America.

If you would like to write an op-ed for the Washington Examiner, please read ourguidelines on submissions here.

Original post:

Defunding Planned Parenthood needs to take priority in the Senate healthcare bill - Washington Examiner

Thousands of genes influence most diseases – Stanford Medical Center Report

A core assumption in the study of disease-causing genes has been that they are clustered in molecular pathways directly connected to the disease. But work by a group of researchers at the Stanford University School of Medicine suggests otherwise.

The gene activity of cells is so broadly networked that virtually any gene can influence disease, the researchers found. As a result, most of the heritability of diseases is due not to a handful of core genes, but to tiny contributions from vast numbers of peripheral genes that function outside disease pathways.

Any given trait, it seems, is not controlled by a small set of genes. Instead, nearly every gene in the genome influences everything about us. The effects may be tiny, but they add up.

The work is described in a paper published June 15 in Cell. Jonathan Pritchard, PhD, professor of genetics and of biology, is the senior author. Graduate student Evan Boyle and postdoctoral scholar Yang Li, PhD, share lead authorship.

The researchers call their provocative new understanding of disease genes an omnigenic model to indicate that almost any gene can influence diseases and other complex traits. In any cell, there might be 50 to 100 core genes with direct effects on a given trait, as well as easily another 10,000 peripheral genes that are expressed in the same cell with indirect effects on that trait, said Pritchard, who is also a Howard Hughes Medical Institute investigator.

Each of the peripheral genes has a small effect on the trait. But because those thousands of genes outnumber the core genes by orders of magnitude, most of the genetic variation related to diseases and other traits comes from the thousands of peripheral genes. So, ironically, the genes whose impact on disease is most indirect and small end up being responsible for most of the inheritance patterns of the disease.

This is a compellingpaper that presents a plausible and fascinatingmodel to explain a number of confusing observations from genomewide studies of disease, said Joe Pickrell, PhD, an investigator at the New York Genome Center, who was not involved in the work.

Until recently, said Pritchard, he thought of genetically complex traits as conforming to a polygenic model, in which each gene has a direct effect on a trait, whether that trait is something like height or a disease, such as autism.

View original post here:

Thousands of genes influence most diseases - Stanford Medical Center Report

New three-in-one blood test opens door to precision medicine for prostate cancer – Medical Xpress

June 19, 2017 Micrograph showing prostatic acinar adenocarcinoma (the most common form of prostate cancer) Credit: Wikipedia

Scientists have developed a three-in-one blood test that could transform treatment of advanced prostate cancer through use of precision drugs designed to target mutations in the BRCA genes.

By testing cancer DNA in the bloodstream, researchers found they could pick out which men with advanced prostate cancer were likely to benefit from treatment with exciting new drugs called PARP inhibitors.

They also used the test to analyse DNA in the blood after treatment had started, so people who were not responding could be identified and switched to alternative therapy in as little as four to eight weeks.

And finally, they used the test to monitor a patient's blood throughout treatment, quickly picking up signs that the cancer was evolving genetically and might be becoming resistant to the drugs.

The researchers, at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust, say their test is the first developed for a precision prostate cancer therapy targeted at specific genetic faults within tumours.

It could in future allow the PARP inhibitor olaparib to become a standard treatment for advanced prostate cancer, by targeting the drug at the men most likely to benefit, picking up early signs that it might not be working, and monitoring for the later development of resistance.

The study is published today (Monday) in the prestigious journal Cancer Discovery. It was funded by the Prostate Cancer Foundation, Prostate Cancer UK, Movember, Cancer Research UK and the National Institute for Health Research (NIHR) via the Experimental Cancer Medicine Centre network, and the NIHR Biomedical Research Centre at The Royal Marsden and The Institute of Cancer Research (ICR).

The test could help to extend or save lives, by targeting treatment more effectively, while also reducing the side-effects of treatment and ensuring patients don't receive drugs that are unlikely to do them any good.

The new study is also the first to identify which genetic mutations prostate cancers use to resist treatment with olaparib. The test could potentially be adapted to monitor treatment with PARP inhibitors for other cancers.

Researchers at the ICR and The Royal Marsden collected blood samples from 49 men at The Royal Marsden with advanced prostate cancer enrolled in the TOPARP-A phase II clinical trial of olaparib.

Olaparib is good at killing cancer cells that have errors in genes that have a role in repairing damaged DNA such as BRCA1 or BRCA2. Some patients respond to the drug for years, but in other patients, the treatment either fails early, or the cancer evolves resistance.

Looking at the levels of cancer DNA circulating in the blood, the researchers found that patients who responded to the drug had a median drop in the levels of circulating DNA of 49.6 per cent after only eight weeks of treatment, whereas cancer DNA levels rose by a median of 2.1 per cent in patients who did not respond.

Men whose blood levels of DNA had decreased at eight weeks after treatment survived an average of 17 months, compared with only 10.1 months for men whose cancer DNA levels remained high.

The researchers also performed a detailed examination of the genetic changes that occurred in cancer DNA from patients who had stopped responding to olaparib. They found that cancer cells had acquired new genetic changes that cancelled out the original errors in DNA repair - particularly in the genes BRCA2 and PALB2 - that had made the cancer susceptible to olaparib in the first place.

The research puts into action the central aim of the ICR's and The Royal Marsden's research strategy, which is to overcome cancer's adaptability, evolution and drug resistance.

Professor Johann de Bono, Regius Professor of Cancer Research at The Institute of Cancer Research, London, and Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust, said:

"Our study identifies, for the first time, genetic changes that allow prostate cancer cells to become resistant to the precision medicine olaparib.

"From these findings, we were able to develop a powerful, three-in-one test that could in future be used to help doctors select treatment, check whether it is working and monitor the cancer in the longer term. We think it could be used to make clinical decisions about whether a PARP inhibitor is working within as little as four to eight weeks of starting therapy.

"Not only could the test have a major impact on treatment of prostate cancer, but it could also be adapted to open up the possibility of precision medicine to patients with other types of cancer as well."

Professor Paul Workman, Chief Executive of The Institute of Cancer Research, London, said:

"Blood tests for cancer promise to be truly revolutionary. They are cheap and simple to use, but most importantly, because they aren't invasive, they can be employed or applied to routinely monitor patients to spot early if treatment is failing - offering patients the best chance of surviving their disease.

"This test is particularly exciting because it is multi-purpose, designed for use both before and after treatment, and using both the absolute amounts of cancer DNA in the bloodstream and also a readout of the specific mutations within that genetic material. We believe it can usher in a new era of precision medicine for prostate cancer."

Professor David Cunningham, Director of Clinical Research at The Royal Marsden NHS Foundation Trust, said:

"This is another important example where liquid biopsies - a simple blood test as opposed to an invasive tissue biopsy - can be used to direct and improve the treatment of patients with cancer."

Dr Matthew Hobbs, Deputy Director of Research at Prostate Cancer UK said:

"To greatly improve the survival chances of the 47,000 men diagnosed with prostate cancer each year, it's clear that we need to move away from the current one-size-fits-all approach to much more targeted treatment methods. The results from this study and others like it are crucial as they give an important understanding of the factors that drive certain prostate cancers, or make them vulnerable to specific treatments.

"However, there is still much more to understand before the potentially huge benefits of widespread precision treatment for prostate cancer will reach men in clinics across the UK. That is why Prostate Cancer UK is investing so heavily in this area, including supporting this research released today."

Explore further: New blood test predicts who will benefit from targeted prostate cancer treatments

A new blood test could predict which men with advanced prostate cancer will respond to new targeted treatments for the disease.

A pioneering cancer drug set to become the first to be approved specifically for inherited cancers could also be used much more widely to treat prostate cancer, a world-leading expert said today.

Men with prostate cancer benefit from treatment with the pioneering drug olaparib - the first cancer drug to target inherited mutations - according to the results of a major trial presented today (Tuesday).

A pioneering drug developed to treat women with inherited cancers can also benefit men with advanced prostate cancer, a major new clinical trial concludes.

Prostate cancer cells depend on signaling through the androgen receptor (AR) to grow and survive. Many anti-cancer therapies that target ARs are initially successful in patients, including a class of drugs known as CYP17A1 ...

The loss of CHD1, one of the most frequently mutated genes in prostate tumors, sensitizes human prostate cancer cells to different drugs, including PARP inhibitors. This suggests CHD1 as a potential biomarker for targeted ...

A large scale study of women carrying faults in important cancer genes should enable doctors to provide better advice and counselling for treatments and lifestyle changes aimed at reducing this risk.

New study results show for the first time how dying cells ensure that they will be replaced, and suggests an ingenious, related new approach to shrinking cancerous tumors. A research team from Rush University Medical Center ...

Compounds from grapes may kill colon cancer stem cells both in a petri dish and in mice, according to a team of researchers.

Rhabdomyosarcoma, a cancer made up of cells that normally develop into skeletal muscles, is the most common soft tissue cancer in children. If it is detected early and localized in certain areas, rhabdomyosarcoma is usually ...

While it's widely held that tumors can produce blood vessels to support their growth, scientists now have evidence that cells key to blood vessel formation can also produce tumors and enable their spread.

Scientists have developed a three-in-one blood test that could transform treatment of advanced prostate cancer through use of precision drugs designed to target mutations in the BRCA genes.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

More here:

New three-in-one blood test opens door to precision medicine for prostate cancer - Medical Xpress

Will patients’ lifestyles become more important to precision medicine than gene sequencing? – Genetic Literacy Project

While much of the excitement surrounding precision medicine focuses on using genomics to tailor personalized treatment plans, speakers at the Precision Medicine Summit said theres more to it.

We cannot achieve precision medicine without having everyone be a participant and benefit and understand, said India Barnard-Hook, director of strategy and associate director of precision medicine at University of California, San Francisco. Precision medicine is about much more than genomics.

Social determinants of health, for instance, typically occur outside the healthcare system and have a significant impact on both health and individual outcomes.

You have to know a lot more than the clinical phenotype, said Linda Chin, chief innovation officer for health affairs at The University of Texas Health System.If you understand all the other factors that contribute to diseases, those can alter the course of the disease and ultimately prevent it.

Penn Medicine associate vice president of health technology and academic computing Brian Wells even made the bold prediction that genetic sequencing may become less relevant as cancer treatments become increasingly sophisticated.

If we discover one immunotherapy that applies to all cancers, we really dont need to sequence your genome anymore, Wells said. Were at a tipping point and sequencing could become less important.

The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion, and analysis. Read full, original post:With precision medicine, social determinants could be more insightful than genetics

Link:

Will patients' lifestyles become more important to precision medicine than gene sequencing? - Genetic Literacy Project

‘Food Evolution’ movie could mark turning point in public GMO discussion – Genetic Literacy Project

Last year a Pew Research poll gauged public sentiment toward genetic engineering of food crops (familiarly, GMO). The results showed that while the public is consumed with fear and suspicion, scientists view the technology as safe and effective.

This divide may be due to the deep presence of non-scientific websites, books and films that abandon science to perpetuate a popular and profitable myth. Fear is their main vehicle. For anti-corporate reasons or simply to promote high-priced, lifestyle-based food products, there are many that create hyperbole and disparaging imagery around the science of genetic engineering. Many opposed to the technology are only experts at producing media targeted to tarnish the favorable applications of these helpful technologies.

Non-scientific media dominates the media. From alarmist pseudo-documentaries like Food Inc. and GMO OMG, to the scientifically painful inept fiction Consumed, media in this space are designed to shock and scare, knowingly at the expense of scientifically precise information. There have been few artistically-driven Hollywood efforts to speak up for the science, telling the evidence-based story to the majority of consumers that simply want to enjoy safe and affordable food produced sustainably.

[Editors Note: Stacy Malkan, co-director of USRight to Know, offers an opposing take on the movie here.]

But this trend is changing with a new series of scientific documentaries. The first film is Food Evolution, directed by Scott Hamilton Kennedy. The documentary examines the issues by taking a close-and-personal look at several global agricultural situations, the personalities involved, the successes, and most painfully, the damaging consequences of our failure to deploy useful technology that can help those in need. Food Evolution conveys a scientific story with imagery, humanity and compassion that scientists never could alone. The film is narrated by Dr. Neil deGrasse Tyson, adding his gravitas to this important topic.

The film centers on political and field situations in Hawaii, Uganda, and other locations throughout the world. The central players are the scientists that understand and share the benefits of these technologies. Scientists like Drs. Alison Van Eenennaam, Dennis Gonsalves, Pamela Ronald and Leena Tripathi, along with former anti-biotech activist and author Mark Lynas, carry the film as a vehicle that takes them through their discussions of the science and their interactions with the public and farmers.

But the film also provides enough rope to the charlatans that pollute a scientific discourse with manufactured fear. Prominent among them is Jeffery Smith, an author and film producer opposed to biotechnology. The film shows how he manipulates language, makes claims, and tweaks the emotions of concerned people to sell his science-challenged message. It exposes the for-profit misgivings of the Food Babe Vani Hari, and the ideologically-charged anti-corporatism of other leaders in an anti-GMO movement that seeks to end the use of biotechnology- even if it hurts those in need. These are the most important aspects of the film because they expose how a cadre of non-experts is willing to bastardize science, and sacrifice progress and people for ideology and profit.

But the real stars of the show are a papaya, a banana, and the people that need them. Their story is shown with stunning imagery and emotion-evoking vignettes that encapsulate the frustrations we feel as scientists with solutions stalled by activist fear-mongering.

Ive seen the film several times, and each time Ive lost tears. As a scientist, it is painful to relive how safe and effective solutions that can change the lives of people and help our planetbut their use is restricted because of well-financed and coordinated misinformation and fear campaigns.

The beauty of Food Evolution is that it will benchmark a time when public sentiment was changing to support a pro-science message. For twenty years we have been told of horrors that never materialized. We have watched products intended to serve humanity languish in public laboratories because of affluent-nation fears. We have witnessed approval of scientifically-baseless legislation restrict choices for farmers. Weve observed the internets profiteers tour the planet and reap personal wealth while lying to the public about science.

But even before the film has been presented in wide release, news of this film has prompted a typical and expected response from anti-biotech activists. They are shouting the tired claims that this is a Monsanto-financed propaganda flick and that nobody should trust it.

Watch for yourself and determine who is lying to you. Is it the politicians, celebrities and scaremongers, or the public, government and company scientists that have dedicated their lives to developing technology to solve problems for people and planet? This film answers that question in remarkable clarity.

Finally, high congratulations to Scott Hamilton Kennedy and his team. While the scientific community has extolled its virtues, it is unclear how the film community will embrace Food Evolution. However, ultimately the filmmakers can revel in the satisfaction that they told the truth at a time when those that stand up are punished for telling the truth. It is a brave, first-class effort that will age impeccably well, and perhaps punctuate the transition to a gentler time where science and reason rule over misinformation and fear.

Food Evolution opens in New York and Los Angeles on June 23rd.

A version of this article appeared at Huffington Post as MOVIE REVIEW: Food Evolution and has been republished here with permission from the authors and the original publisher.

Kevin Folta is professor and chairman of the Horticultural Sciences Department at the University of Florida, Gainesville. Dr. Folta researches the functional genomics of small fruit crops, the plant transformation, the genetic basis of flavors, andstudies at photomorphogenesis and flowering. He has also written many publications and edited books, most recently the 2011 Genetics, Genomics, and Breeding of Berries. Follow him on Twitter@kevinfolta

Link:

'Food Evolution' movie could mark turning point in public GMO discussion - Genetic Literacy Project

Engineered algae puts half of its carbon into fats for biofuels – Ars Technica

Enlarge / This raceway pond is used for continuous growth of biofuel-producing microbes.

There's an inherent tension in convincing organisms to produce fuel for us. To grow and thrive, the organism has to direct its energy into a variety of chemicalsproteins, fats, DNA, and more. But for biofuels, we're mostly interested in fats, which are long-chain hydrocarbons that already look a lot like our liquid fuels. Fat is easy to convert into biodiesel, for example.

So how do we convince an organism to do what we want, rather than what it needs? There have been two approaches to this so far. One is to take an organism that we understand well and engage in genetic engineering to direct its metabolism toward fuel production. The second approach is to search for organisms that naturally produce lots of the chemicals we're interested in.

Now, researchers at the company Synthetic Genomics have taken what you might consider a hybrid approach. They've started with an algae that will produce oodles of fat, but only if you stop its growth by starving it of essential nutrients. And, by studying how this starvation response works, the scientists identified a key regulator and altered its activity. The engineered strain produces nearly as much fat as the normal strain, but it does so while continuing to grow.

The species in question is a single-celled algae called Nannochloropsis gaditana. It has two properties that make it great for biofuel production. One is that it's part of a genus that is happy to grow in salt and brackish water, meaning that biofuel production doesn't have to compete for fresh water. The second property is that it naturally produces a slew of fats (largely triacylglycerols). Starving Nannochloropsis for an essential nutrient (nitrogen) causes the algae to convert its spare energy to fat for storage, allowing it to ride out the adverse conditions. These lipids can end up accounting for 60 percent of the cells' dry weight.

Unfortunately, starving the Nannochloropsis algae isn't exactly conducive to continued growth. Rather than having a nice, continuously expanding culture that you can pull cells out of for fuel production, the entire population has to go through a boom-bust cycle. Researchers have tried for years to engineer a similar response that doesn't require starvation, but their efforts have been slowed by the fact that there are no genetic tools for engineering Nannochloropsis, and we don't know enough about the biology of its starvation process to really understand what to target.

The new work from Synthetic Genomics deals with both of these hurdles. To start with, the company's researchers got the CRISPR-Cas gene-editing system working in Nannochloropsis. That allows them to target any gene they'd like for deletion, modification, or replacement.

But they also worked on understanding how the starvation process gets triggered. Changes in fat metabolism start to become apparent about five hours after all nitrogen sources are taken out of the culture. So, the team reasoned, changes in gene activity have to come before that. After three hours of starvation, the researchers looked for changes in the activity of a specific class of genes: those that bind to DNA and regulate nearby genes. These, they reasoned, could be controlling the starvation process.

They came up with a list of 20 genes. The researchers then targeted 18 of them individually for elimination using the CRISPR editing system.

One of these 18 genes, called ZnCys, turned out to be exactly what the researchers were hoping to find. Eliminating the gene caused the algae to build up three times more fat as the normal strain. Unfortunately, the edited version also acted like it was starving, with growth slowing to a crawl. As a result, the normal strain would outproduce the gene-edited version over the long run.

To get around this issue, the researchers started targeting sites near the part of the gene that encodes a protein. These nearby sequences often help control the amount of protein produced from a gene, so disrupting them could produce a version of the ZnCys that had lower activity than normal but wasn't completely shut down. Their plan worked; the researchers ended up with three new strains, which saw ZnCys activity reduced by 20, 50, and 70 percent, giving them a nice range to test.

To an extent, all of the new strains worked. While total productivity of the three engineered lines was down compared to a normal strain, it was only down by anywhere from five to 15 percent. While there were definitely fewer cells, they incorporated large quantities of carbon, and they converted more than twice as much of it to lipids. This more than made up for the drop in cell number. Critically, the strains did fine in a continuous culture, meaning that you could siphon off 70 percent of the cells each day for biofuel production without shutting the whole culture down.

A closer examination of gene activity in the cells showed that the engineered versions had reduced activity of genes involved in importing and assimilating nitrogen. So even when nitrogen was present, the cells weren't able to use as much of it, which nicely explains why they acted like they were semi-starving.

Ideally, I expect that Synthetic Genomics would prefer to generate a strain that produces a lot of lipids even when the strain is not nitrogen starved at all. As a result, the company probably viewed ZnCys as a bit of a disappointmentSynthetic Genomics would have probably preferred a gene that simply switched the metabolism into lipid production mode without messing with nitrogen.

Still, the study provides some indication of how the nitrogen response is regulated. One of the other 18 genes the researchers looked at (or the two they didn't) may or may not be more directly involved in lipid production, but it didn't show good performance in this screen because it had so many other effects. No doubt the team is continuing to dissect the pathways that get activated when nitrogen becomes limited.

And, in the mean time, the researchers have a strain that can do continuous biofuel production at double the rate of the normal onewhich is certainly better than what they started with.

Nature Biotechnology, 2017. DOI: 10.1038/nbt.3865 (About DOIs).

Link:

Engineered algae puts half of its carbon into fats for biofuels - Ars Technica

GE and the Mayo Clinic back software to bring cancer-fighting gene … – TechCrunch

Behind the incredible process of developing targeted gene therapies to fight diseases like cancer lies an incredibly mundane problem that prevents these treatments from getting to patients paperwork and procedures.

While $5.7 billion was invested in companies developing cellular and genetic therapies, and with 800 clinical trials initiated worldwide and the first two CAR-T cell therapies expected to launch into market later this year, businesses still saythe ability to get these treatments to patients is limited by paperwork, supply chain management, and last mile delivery.

So GE (through its GE Ventures arm), the Mayo Clinic (through Mayo Clinic Ventures) and the venture investment firm DFJ have invested $13.75 million to back Vineti a software platform the companies are billing as a solution to gene therapys supply chain problem.

Its only the sixth company to have actually been built by GEs internal business team and spun out by the conglomerates venture arm.

According to company co-founder and former GE Ventures managing director Amy DuRoss, the process for developing and managing gene therapies is critical to the success of the treatment.

Amy DuRoss, chief executive at Vineti

To that end, Vinetis software tracks logistics, manufacturing and clinical data to improve treatments and drive down the cost of these therapies (which are mainly only accessible to those people with the very best health plans).

The startups technology was actually born out of necessity (always the mother of invention) and came from conversations that GE was having with a large, undisclosed customer.

A pharma company that is a regular client of GE Healthcare said we are solving late stage cancer and we want to take this commercial but we have not got the technology that can ensure that we can scale out these technologies in the commercial phase, DuRoss told me.

GEs healthcare business then took the problem to the companys venture investment and new business arm and began the development process of building a business.

In addition to DuRoss, who has been a luminary in the life sciences field since she helped with the push to get stem cell research approved in California; Vineti has a murderers row of leading healthcare talent.

Chief strategy officer Heidi Hagen, was the former SVP of Operations for cell immunotherapy pioneer Dendreon; chief technology officer Razmik Abnous was the chief technology officer at the healthcare data management juggernaut Documentum; and Malek Faham, the companys chief science officer, literally worked on some of the foundational science for gene therapies.

While the companys technology could have applications for a number of different treatments, and be used for several kinds of therapies, the focus, for now, is on cancer.

Cancer is a bullseye, says DuRoss. It is arguably the biggest cause of human suffering [and] there are treatments already in phase three, that if brought to market effectively could mark a turning point in medicines battle against the deadly disease, she said.

We see an opportunity as data accrues to the system over time for a use case in predicting therapy based on outcome data but were not making these claims today, said DuRoss.

Mayo Ventures had been working with GE for two years from the initial concept to the close of this new round of financing for Vineti. Its one of only 15 companies that the Clinic has backed since the formation of Mayo Clinic Ventures, and according to Andy Danielsen, the vice chair of Mayo Clinic Ventures.

One thing with Vineti that we liked is that we have a commitment to cell and gene therapies at Mayo, said Danielsen, so the interests were aligned. Vineti will make the gene and cell therapy production process more efficient and as a result, less costly. Its all part of the equation of making these therapies more affordable and opening them up to a greater number of people.

Therapy supply chain

External ordering pages

Product tracking

Therapy scheduling

Identity verification

Original post:

GE and the Mayo Clinic back software to bring cancer-fighting gene ... - TechCrunch

Brammer Bio Appoints Leading Commercial Manufacturing And Gene Therapy Expert As Chief Manufacturing Officer – PR Newswire (press release)

"We are thrilled to have Chris join Brammer at this key time of our growth. Chris brings a unique blend of commercial and clinical manufacturing experience with deep gene therapy knowledge and an outstanding leadership ethos that will strengthen Brammer's presence as the best in class gene therapy CDMO," said Mark Bamforth, Brammer's President and CEO.

Chris started his career at American Cyanamid (now Pfizer) in Pearl River, NY, where he held positions in quality control, viral vaccine development, and bulk manufacturing.He later joined BioReliance in Rockville, MD, with responsibility for US contract manufacturing operations, focused primarily on viral vector manufacturing and cell banking in support of gene therapy pre-clinical and clinical studies.

Regarding joining Brammer, Chris shared, "I am passionate about the gene therapy industry and excited to be joining the leading gene therapy CDMO.Gene therapy will improve lives and transform healthcare in the coming years.Brammer is uniquely positioned with exceptional scientific know-how and top class manufacturing and quality operations. I am delighted to join a team that has honed its expertise through the delivery of over 150 clinical batches and is now preparing to supply phase III and commercial gene therapy products for clients."

"Chris's experience manufacturing viral vectors and his understanding of their quality attributes together with his commercial manufacturing track record is unique. He is a great addition to our team," noted Richard Snyder, Ph.D., Brammer's CSO.

Chris holds a Bachelor's degree in Biological Sciences from Rutgers University Cook College and a Master's degree in Biochemistry from New York Medical College. Chris is active in the community including serving as Vice Chairman, Board of Directors for Massachusetts Biotechnology Education Foundation and on the Board of Directors for the West End House Boys and Girls Club of Boston.

About BrammerBrammer Bio is a leading CDMO providing clinical and commercial supply of vectors for in vivo gene therapy and ex vivo modified-cell based therapy, along with process and analytical development, and regulatory support, enabling large pharma and biotech clients to accelerate the delivery of novel medicines to improve patients' health. Brammer is owned by Ampersand Capital Partners, the only institutional investor in the company, and its founders. For more information, please visit http://www.brammerbio.com

Media Contacts

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/brammer-bio-appoints-leading-commercial-manufacturing-and-gene-therapy-expert-as-chief-manufacturing-officer-300476421.html

SOURCE Brammer Bio

http://www.brammerbio.com

See the original post:

Brammer Bio Appoints Leading Commercial Manufacturing And Gene Therapy Expert As Chief Manufacturing Officer - PR Newswire (press release)

Cell Medica Acquires WT1 Cancer Immunotherapy from Cell and … – Business Wire (press release)

LONDON--(BUSINESS WIRE)--Cell Medica today announced the acquisition of Catapult Therapy TCR Limited, a subsidiary of Cell and Gene Therapy Catapult (CGT Catapult), and the initiation of a collaboration to establish cell therapy manufacturing for Cell Medica at CGT Catapults GMP manufacturing facility in Stevenage, UK. Financial terms were not disclosed.

Catapult Therapy TCR Ltd is a special purpose company set up by CGT Catapult, UCL Business and Imperial Innovations, and managed by CGT Catapult, for the development of the WT1 T cell receptor (TCR) cell therapy discovered through research at University College London (UCL) and Imperial College London. The WT1-TCR cell therapy enhances the immune system to fight cancer by genetically engineering the patients T cells to target WT1, a tumour-associated antigen which is expressed in both solid tumours and blood cancers.

CGT Catapult has been developing the WT1-TCR cell therapy for the treatment of acute myeloid leukaemia and myelodysplastic syndrome. Early development work, including initiation of a Phase I trial, was conducted at UCL and Imperial College London with funding from the UK charity Bloodwise. CGT Catapult advanced the product to a larger Phase I/II clinical trial and developed an improved manufacturing process. Having completed the treatment of eight patients with promising results, CGT Catapult will now transfer the WT1-TCR cell therapy rights to Cell Medica for continued development towards regulatory approval.

The WT1-TCR cell therapy will be integrated with the Dominant TCR platform technology which Cell Medica licensed from UCL Business in 2016. Applying the Dominant TCR technology to the WT1-TCR cell therapy is expected to result in a more efficacious product with the potential to treat patients with solid tumours such as mesothelioma and ovarian cancer, which have proven very difficult to treat with conventional therapies. Cell Medica is planning to initiate a Phase I/II clinical trial with a Dominant WT1-TCR version in late 2018.

Cell Medica and CGT Catapult have also initiated a collaboration to establish cell therapy manufacturing operations for Cell Medica at the GMP production facility recently built by CGT Catapult in Stevenage. The collaboration will include transferring the current WT1-TCR cell therapy manufacturing process to Stevenage over the next twelve months while Cell Medica and CGT Catapult work to develop a commercial scale production process using advanced manufacturing techniques. Cell Medica will also evaluate the feasibility of manufacturing additional cell therapy products at the site.

The acquisition of the WT1-TCR cell therapy leverages the investment we made in 2016 for exclusive rights to the Dominant TCR technology, said Gregg Sando, CEO of Cell Medica. Our objective is to show how we can enhance any existing TCR cell therapy with the Dominant TCR technology to create a more effective treatment for patients with solid tumours who otherwise have a very poor prognosis. We are also looking forward to an important collaboration with CGT Catapult to initiate manufacturing at the Stevenage GMP facility where we will work together on scale-up strategies for commercial production.

About Cell Medica

Cell Medica is committed to transforming patients lives through developing the significant therapeutic potential of cellular immunotherapy for the treatment of cancer. In collaboration with our strategic partners, Cell Medica is developing a range of products using three proprietary technology platforms including activated T cells, chimeric antigen receptors (CARs) and engineered T cell receptors (TCRs). Our lead product is CMD-003 is being tested in an international Phase II trial for the treatment of cancers associated with the oncogenic Epstein Barr virus. We are working with the Baylor College of Medicine and the University of North Carolina to develop next generation CAR-modified NKT cells including an off-the-shelf product. In the field of engineered TCRs, we are collaborating with University College London to develop the Dominant TCR technology platform. Cell Medica is headquartered in London with subsidiaries in Zurich and Houston.

About the Cell and Gene Therapy Catapult

The Cell and Gene Therapy Catapult was established as an independent centre of excellence to advance the growth of the UK cell and gene therapy industry, by bridging the gap between scientific research and full-scale commercialisation. With more than 120 employees focusing on cell and gene therapy technologies, it works with partners in academia and industry to ensure these life-changing therapies can be developed for use in health services throughout the world. It offers leading-edge capability, technology and innovation to enable companies to take products into clinical trials and provide clinical, process development, manufacturing, regulatory, health economics and market access expertise. Its aim is to make the UK the most compelling and logical choice for UK and international partners to develop and commercialise these advanced therapies. The Cell and Gene Therapy Catapult works with Innovate UK. For more information please visit ct.catapult.org.uk or visit http://www.gov.uk/innovate-uk.

Original post:

Cell Medica Acquires WT1 Cancer Immunotherapy from Cell and ... - Business Wire (press release)